First Time Loading...

Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 6.93 AUD -2.39% Market Closed
Updated: Apr 28, 2024

Mayne Pharma Group Ltd
Cash from Financing Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Mayne Pharma Group Ltd
Cash from Financing Activities Peer Comparison

Comparables:
RCE
NEU
BOT
PBP
C
CU6

Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Financing Activities CAGR 3Y CAGR 5Y CAGR 10Y
Mayne Pharma Group Ltd
ASX:MYX
Cash from Financing Activities
-AU$431.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Recce Pharmaceuticals Ltd
ASX:RCE
Cash from Financing Activities
AU$9m
CAGR 3-Years
-30%
CAGR 5-Years
76%
CAGR 10-Years
N/A
Neuren Pharmaceuticals Ltd
ASX:NEU
Cash from Financing Activities
AU$3.6m
CAGR 3-Years
-43%
CAGR 5-Years
-21%
CAGR 10-Years
-18%
Botanix Pharmaceuticals Ltd
ASX:BOT
Cash from Financing Activities
AU$36.2m
CAGR 3-Years
N/A
CAGR 5-Years
11%
CAGR 10-Years
46%
Probiotec Ltd
ASX:PBP
Cash from Financing Activities
-AU$11.1m
CAGR 3-Years
N/A
CAGR 5-Years
-1%
CAGR 10-Years
0%
C
Clarity Pharmaceuticals Ltd
ASX:CU6
Cash from Financing Activities
AU$231.6k
CAGR 3-Years
-70%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Mayne Pharma Group Ltd's Cash from Financing Activities?
Cash from Financing Activities
-431.9m AUD

Based on the financial report for Jun 30, 2023, Mayne Pharma Group Ltd's Cash from Financing Activities amounts to -431.9m AUD.